acetrizoate

Trade name: salpix

Small moleculeapproved

Approved

Apr 30, 1953

Acetrizoic acid (trade names Gastrografina, Urografina in Portugal) is a palatable lemon-flavored water-soluble iodinated radiopaque X-ray contrast medium for oral or rectal administration only. Acetrizoic acid is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. Administration of hypertonic Gastrografin solutions may lead to hypovolemia and hypotension due to fluid loss from the intestine. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Timeline

1950s

Apr 30, 1953
Johnson and Johnson — Earliest FDA Approval
Apr 30, 1953
Johnson and Johnson — NDA Secondary Org
Apr 30, 1953
Johnson and Johnson — NDA Organization

Indications

Approved for

Mechanism of action

contrast mediumRadiopaque
contrast medium radiopaque

Approval history

approvedApr 30, 1953

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I

Mol. weight: 556.86 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Topical
Availability: Discontinued

Oral

Parenteral

Topical

Yes

Sources

Also known as

acetrizoate
acetrizoate
acetrizoate
acetrizoate sodium
acetrizoate sodium
acetrizoate sodium
acetrizoate sodium
acetrizoate sodium
acetrizoate sodium
acetrizoate sodium
acetrizoic acid
acetrizoic acid
acetrizoic acid
acetrizoic acid
acetrizoic acid
opacaron
salpix
salpix
sodium acetrizoate
sodium acetrizoate
sodium acetrizoate
sodium acetrizoate
urokon
urokon
urokon
urokonic acid

Organizations

Marketing (2)

Organization	Org type	Relationship	Date
Johnson and Johnson	For profit	NDA2	Apr 30, 1953
Johnson and Johnson	For profit	NDA	Apr 30, 1953